MiR Diagnostics, LLC is a precision healthcare company based in Rensselaer, NY, dedicated to transforming cancer management globally. Their proprietary miR Disease Management Platform revolutionizes the standard of value-based care for urological cancers, starting with the miR Sentinel Prostate Cancer Test, a non-invasive liquid biopsy urine test that accurately detects, classifies, and monitors prostate cancer at the molecular level.
With a focus on providing actionable answers to the most important questions, the miR Sentinel Prostate Cancer Test delivers accurate and actionable results from a single urine sample, answering whether there is evidence of prostate cancer and the severity of the risk. This innovative approach aims to improve early detection and effective disease management, addressing the inefficiencies and limitations of current standard procedures.
Generated from the website